# US 10,478,418 B2 · Inhibited expression of PD-L1 and enhanced expression of PD-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,418 B2
- Document ID: US10478418B2
- Status: Granted
- Kind: B2
- Application number: 16/128,786
- Filed: 2018-09-12
- Published: 2019-03-14
- Granted: 2019-11-19
- Earliest claimed: 2017-09-13
- Assignees: IN Ingredients, Inc.
- Applicants: IN Ingredients, Inc.
- Inventors: Augustin T. Romero; Bolin Qin
- Web page: https://patentgrep.com/patent/US10478418B2

## CPC

- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/49: Fagaceae (Beech family), e.g. oak or chestnut
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/63: Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K 36/73: Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.

## Claims

### Claim 1

A method of treating a glioma in a human in need thereof comprising administering to said human in need thereof a composition comprising at least 5.0 weight % isolated cinnamtannin D-1, at least 5.0 weight % isolated cinnamtannin B-1, or a combination thereof to effectively treat the glioma in said human in need thereof.

### Claim 2 (depends on 1)

The process of claim 1, wherein said cinnamtannin D-1 and/or cinnamtannin B-1 is present is said composition at about 1-30 milligrams.

### Claim 3 (depends on 1)

The process of claim 1, wherein said cinnamtannin D-1 and/or cinnamtannin B-1 is present in said composition at about 3-10 milligrams.

### Claim 4 (depends on 1)

The process of claim 1, wherein said composition consists essentially of cinnamtannin D-1 and cinnamtannin B-1.

### Claim 5 (depends on 1)

The process of claim 1, wherein the composition is administered orally, intravenously, by intramuscular injection, by intraperitoneal injection, or transdermally.

### Claim 6 (depends on 1)

The process of claim 1, wherein said composition further comprises one or more vitamins, antioxidants, or combinations thereof.

### Claim 7 (depends on 1)

The process of claim 1, wherein said composition is administered daily for a period of six weeks or more.

### Claim 8 (depends on 1)

The process of claim 1, wherein said composition is administered one to three times daily.